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a  b  s  t  r  a  c  t
The  present  study  was  to evaluate  the  protective  role of  hesperidin  (HDN)  against  iron-
induced  hepatic  and  renal  toxicity  in  rats.  Administration  of  iron  (30 mg/kg  body  weight)
intraperitoneally  for 10  days,  the  levels  of serum  hepatic  markers,  renal  functional  markers,
lipid  proﬁle,  lipid  peroxidation  markers  and iron  concentration  in blood  were signiﬁcantly
(p  < 0.05)  increased.  The  toxic  effect  of iron  was  also indicated  by  signiﬁcant  (p < 0.05)
decrease  in the  levels  of  plasma,  liver  and kidney  of  enzymatic  and  non-enzymatic  antiox-
idants.  Administration  of hesperidin  at different  doses  (20,  40  and  80  mg/kg  body  weight)
signiﬁcantly  (p  <  0.05)  reversed  the  levels  of  serum  hepatic  markers,  renal  functional  mark-
ers,  lipid  proﬁle,  lipid peroxidation  markers,  restored  the  levels  of  hepatic,  renal  enzymatic
antioxidants  and non-enzymatic  antioxidants  with  decrease  in iron  concentration  in blood.
Hesperidin at a dose  of  80 mg/kg  body  weight  exhibits  signiﬁcant  protection  on hepaticAntioxidant
Lipid peroxidation
and  renal  when  compared  with  other two  doses  (20  and  40 mg/kg  body  weight).  All  these
changes  were  corroborating  by histological  observations  of liver and  kidney.  This  study
demonstrated  the protective  role  of  hesperidin  in reducing  toxic  effects  of iron  in  experi-
mental  rats.
©  2014  Published  by  Elsevier  Ireland  Ltd. This  is  an  open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Heavy metals can be classiﬁed as potentially toxic
(arsenic, cadmium, lead, etc.), probably essential (vana-
dium, cobalt) and essential (copper, zinc, iron, manganese,
etc.). Toxic elements can be very harmful even at low
concentration when ingested over a long time period [1].
They might come from the soil, environment, fertilizers
and/or metal-containing pesticides, introduced during the
production process or by contamination from the metal
∗ Corresponding author. Tel.: +91 4144 238343; fax: +91 4144 238145.
E-mail address: jayampari@gmail.com (L. Pari).
http://dx.doi.org/10.1016/j.toxrep.2014.11.003
2214-7500/© 2014 Published by Elsevier Ireland Ltd. This is an open access
licenses/by-nc-nd/3.0/).processing equipment. Food consumption had been iden-
tiﬁed as the major pathway of human exposure to toxic
metals, compared with other ways of exposure such as
inhalation and dermal contact [2].
Humans are constantly exposed to hazardous pollut-
ants in the environment-for example, in the air, water,
soil, rocks, diet or workplace. Trace metals are important
in environmental pathology because of the wide range of
toxic reactions and their potential adverse effects on the
physiological function of organ systems. Exposures to toxic
trace metals have been the subject of numerous environ-
mental and geochemical investigations, and many studies
have been published on the acute and/or chronic effects
of high-level exposures to these types of agents; however,
 article under the CC BY-NC-ND license (http://creativecommons.org/
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mFig. 1. Structure of hesperidin.
uch fewer data are available concerning the health effects
f low-dose chronic exposure to many trace metals [3].
Iron is an important trace element of the body, being
ound in functional form in hemoglobin, myoglobin,
ytochrome enzymes with iron sulphur complexes [4].
iver is one of the largest organs in the human body and the
ain site for intense metabolism and excretion [5]. Hepa-
otoxicity is the most common ﬁnding in patients with iron
verloading as liver is mainly the active storage site of iron
n our body [6]. Hydroxy radical may  form due to excess
ron concentration in kidney that leads to progression of
ubular injury. Clinical evidence showed that iron deposi-
ion in kidney associated with the anemia during kidney
iseases [7].
Although an optimum level of iron is always main-
ained by the cells to balance between essentiality and
oxicity, in some situations it is disrupted, resulting
n iron overload which is associated to the oxidative
tress induced disorders including anemia, heart failure,
epatocellular necrosis and cirrhosis [8]. In iron overload-
nduced diseases, iron removal by iron chelation therapy
s an effective life-saving strategy. Iron overload increases
he formation of reactive oxygen species (ROS) which
nvolves the initiation of lipid peroxidation, protein oxi-
ation and liver ﬁbrosis. However, excess iron is stored
s Fe3+ in ferritin and iron overload sustains for long
eriod and released depends on the efﬁciency of iron
helating drugs [9]. The currently available iron-chelating
gents used clinically are deferoxamine, 1,2-dimethyl-
-hydroxypyrid-4-one (deferiprone, L1), and deferasirox
10]. The body lacks to excrete excessive iron and there-
ore the interest has been focused to develop the potent
helating agent capable of complexing with iron and pro-
oting its excretion.
Flavonoids are phenolic compounds abundantly dis-
ributed in plants. It has been reported that most of them
re effective antioxidants [11]. They were suggested to
resent a good scavenger to iron ions [12]. Hesperidin
3,5,7-trihydroxy ﬂavanone-7-rhamnoglucoside) is a phar-
acologically active bioﬂavonoid found in citrus fruits,
ith good free radical scavenging as well as anti-lipid
eroxidation properties in biological membranes [13]. Hes-
eridin (Fig. 1) possesses highest reducing power, chelating
ctivity on Fe2+, hydrogen radical scavenging and hydro-
en peroxide scavenging activities when compared with
atural and synthetic antioxidants such as -tocopherol,
scorbic acid, butylated hydroxytoluene (BHT), butylated
ydroxyanisole (BHA) and trolox [14]. Clinical and experi-
ental data showed the antihypertensive, lipid-lowering,orts 2 (2015) 46–55 47
insulin-sensitizing, antioxidative and anti-inﬂammatory
properties of hesperidin [15]. However, the protective
role of hesperidin against iron-induced liver and kidney
injury has not been investigated. Hence we  proposed to
investigate whether administration of hesperidin offers
protection against iron-induced liver and kidney injury.
2. Materials and Methods
2.1. Chemicals and drugs
Hesperidin (PubChem CID: 10621); ferrous sulfate
(PubChem CID: 24393); 2-thiobarbituric acid (PubChem
CID: 2723628); butylated hydroxytoluene (PubChem
CID 31404); reduced glutathione (PubChem CID:745);
2,2′-dipyridyl (PubChem CID: 1474); xylenol orange
(PubChem CID: 73041); 2,4-dinitrophenylhydrazine (Pub-
Chem CID:CID: 3772977); -glutamyl-p-nitroanilide (Pub-
Chem CID: 3772977); 5,5′-dithiobis(2-nitrobenzoic acid)
(PubChem CID: 6254); trichloroacetic acid (PubChem
CID: 6421); phenazine methosulfate (PubChem CID
9285); nitroblue tetrazolium (PubChem CID: 9281);
reduced nicotinamide adenine dinucleotide (PubChem
CID: 439153); 1-chloro-2,4-dinitrobenzene (PubChem CID:
6) were obtained from Sigma Chemical Co. (St. Louis,
MO,  USA). The rest of the chemicals were obtained from
S.D. Fine Chemicals Mumbai, India and were of analytical
grade.
2.2. Experimental animals
Adult male albino rats of Wistar strain (200–220 g)
were used for the experiment. The animals were housed
in polypropylene cages and maintained in 12-h light/12-
h dark cycle, 50% humidity and 25 ± 2 ◦C. The animals had
free access to standard pellet diet (M/S. Pranav Agro Indus-
tries Ltd., Bangalore, India) and water ad libitum. This study
was approved (Vide. No. 644, 2009) by Institutional Animal
Ethics Committee of Annamalai University and the study
conducted in accordance with the “Guide for the Care and
Use of Laboratory Animals”.
2.3. Experimental design
Ferrous sulfate (30 mg/kg body weight) was dissolved
in isotonic saline and injected intraperitoneally (i.p). Hes-
peridin powder was  dissolved in 0.1% carboxy methyl
cellulose and each rat received daily 1 ml  at a dose of 20,
40 and 80 mg/kg body weight orally by intragastric tube
throughout the experimental period.
The animals were randomly divided into six groups of
six rats in each group.
Group I: served as control (isotonic saline).
Group II: animals were orally administered with hes-
peridin alone (80 mg/kg body weight).
Group III: animals received ferrous sulfate (30 mg/kgbody weight).
Group IV–VI: animals were treated with ferrous sulfate
(30 mg/kg body weight) following oral administration of
hesperidin (20, 40, 80 mg/kg body weight) for 10 days.
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At the end of the experimental period, animals in differ-
ent groups were sacriﬁced by cervical decapitation. Blood
samples were collected without heparin for serum sep-
aration. Serum separated by centrifugation was used for
various biochemical estimations.
2.4. Preparation of tissue homogenate
Rats were anesthetized by ketamine (28 mg/kg body
weight, intra muscularly) and the animals were sacriﬁced
by cervical decapitation. The liver and kidney was  quickly
excised, rinsed with isotonic saline, blotted dry on ﬁlter
paper, weighed and then 10% (w/v) homogenates of tis-
sue was prepared in buffer (0.1 M Tris-HCL buffer (pH 7.4)
and centrifuged at 3000 × g for 20 min  at 4 ◦C. The result-
ing tissue homogenate was used for various biochemical
assays.
2.5. Assessment of serum hepatic marker enzymes
The activities of serum aspartate aminotransferase
(E.C.2.6.1.1), alanine aminotransferase (E.C.2.6.1.2), alka-
line phosphatase (E.C.3.1.3.1) and lactate dehydrogenase
(E.C.3.1.3.1) were assayed using commercially available
diagnostic kits (Sigma diagnostics (I) Pvt. Ltd., Baroda,
India). Gamma  glutamyl transferase (E.C.2.3.2.2) activity
was determined by the method of Rosalki et al. [16] using -
glutamyl-p-nitroanilide as substrate. Based on Vanden Berg
reaction, serum bilirubin was estimated by the method of
Malloy and Evelyn [17].
2.6. Assessment of renal functional marker enzymes
The activities of urea, creatinine and were estimated by
Agappe Diagnostic (I) Pvt. Ltd., Kerala, India. Haemoglobin
was estimated by Drabkin and Austin [18]. Creatinine clear-
ance as an index of glomerular ﬁltration rate was  calculated
from creatinine level in serum and creatinine level in 24 h
urine sample.
2.7. Assessment of iron concentration
For determination of iron in blood, 1 ml  of blood was
digested with nitric acid in microwave oven. After diges-
tion, iron was continuously pre concentrated and deter-
mined by ﬂame atomic absorption spectrophotometry. A
Perkin-Elmer 5000 atomic absorption spectrometer fur-
nished with an iron hollow-cathode lamp (lamp current
4 mA)  was used to determine the iron concentration. The
instrument was set at 228.8 nm with a slit width of 0.5 nm.
The acetylene ﬂow rate was 2.0 l/min and an airﬂow rate of
17.0 l/min was  employed to ensure an oxidizing ﬂame.
2.8. Assessment of lipid proﬁleLipids extracted from the tissues using by the method of
Folch et al. [19]. The levels of total cholesterol, triglycerides
and free fatty acids in the serum and tissues were estimated
by the methods of Zlatkis et al., Fossati and Prencipe, Falholtorts 2 (2015) 46–55
et al. [20–22], respectively. The phospholipids estimation
was  done by the method of Zilversmit and Davis [23].
2.9. Assessment of lipid peroxidation
Lipid peroxidation in plasma, liver and kidney was
estimated spectrophotometrically by measuring thiobarbi-
turic acid reactive substances and lipid hydroperoxides by
the method of Niehius and Samuelson, Jiang et al. [24,25],
respectively.
2.10. Assessment of enzymatic antioxidants
Superoxide dismutase activity was determined by the
method of Kakkar et al. [26]. The activity of catalase
was  determined by the method of Sinha et al. [27]. Glu-
tathione peroxidase activity was  estimated by the method
of Rotruck et al. [28]. Glutathione S-transferase activity was
determined by the method of Habig et al. [29].
2.11. Assessment of non-enzymatic antioxidants
Vitamin C concentration was  measured as previously
reported Omaye et al. [30]. Vitamin E (-tocopherol) was
estimated by the method of Desai et al. [31]. Reduced glu-
tathione was  determined by the method of Ellman et al.
[32].
2.12. Histological Observation
The liver and kidney sample ﬁxed for 48 hr in 10%
formalin were dehydrated by passing successfully in differ-
ent mixture of ethyl alcohol–water, cleaned in xylene and
embedded in parafﬁn. Sections of liver and kidney (5–6 m
thick) were prepared and then stained with hematoxylin
and eosin dye, which mounted in neutral DPX medium for
microscopic observations.
2.13. Statistical Analysis
Values are given as means ± S.D for six rats in each
group. Data were analyzed by one-way analysis of variance
followed by Duncan’s Multiple Range Test (DMRT) using
SPSS version 13 (SPSS, Chicago, IL). The limit of statistical
signiﬁcance was set at (p < 0.05) and the values sharing a
common superscript did not differ signiﬁcantly.
3. Results
3.1. Effect of hesperidin on serum hepatic markers
Table 1 depicts the levels of serum hepatic markers
in control and experimental rats. In Fe treated rats, the
activities of serum hepato-speciﬁc enzymes such as aspar-
tate aminotransferase, alanine aminotransferase, alkaline
phosphatase, lactate dehydrogenase, gamma  glutamyl
transferase and the levels of bilirubin were signiﬁcantly
increased (p < 0.05). Administration of hesperidin signiﬁ-
cantly reversed these changes in a dose dependent manner.
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Table  1
Effect of hesperidin on iron-induced activities of serum hepatic markers in control and experimental rats.
Groups Control Normal + HDN
(80 mg/kg)
Normal + Fe
(30 mg/kg)
Fe
(30 mg/kg) + HDN
(20 mg/kg)
Fe
(30 mg/kg) + HDN
(40 mg/kg)
Fe
(30 mg/kg) + HDN
(80 mg/kg)
AST (IU/l) 56.61 ± 4.25a 57.11 ± 4.51a 87.70 ± 6.31b 79.44 ± 6.01c 72.23 ± 5.59d 64.02 ± 4.83e
ALT (IU/l) 27.34 ± 2.06a 28.27 ± 2.62a 46.61 ± 3.15b 40.73 ± 2.97c 35.41 ± 2.75d 31.79 ± 2.70e
ALP (IU/l) 90.17 ± 8.14a 91.63 ± 8.08a 144.31 ± 11.34b 131.74 ± 11.50c 119.70 ± 9.96d 105.51 ± 9.66e
LDH (IU/l) 107.60 ± 8.58a 107.46 ± 8.60a 167.65 ± 14.16b 151.52 ± 11.87c 136.94 ± 10.63d 121.36 ± 10.09e
GGT (IU/l) 0.68 ± 0.05a 0.69 ± 0.05a 1.21 ± 0.13b 1.08 ± 0.06c 0.97 ± 0.06d 0.83 ± 0.05e
Bilirubin (mg/dl) 0.74 ± 0.06a 0.72 ± 0.06a 1.25 ± 0.10b 1.06 ± 0.09c 0.94 ± 0.65d 0.84 ± 0.07e
Values are mean ± SD for 6 rats in each group. Values are not sharing a common superscript letter (a, b, c, d and e) differ signiﬁcantly at p < 0.05 (DMRT).
HDN—hesperidin, Fe—ferrous sulfate.
Table 2
Effect of hesperidin on the levels renal functional markers in control and experimental rats.
Groups Control Normal + HDN
(80 mg/kg)
Normal + Fe
(30 mg/kg)
Fe (30 mg/kg) + HDN
(20 mg/kg)
Fe (30 mg/kg) + HDN
(40 mg/kg)
Fe (30 mg/kg) + HDN
(80 mg/kg)
Urea in serum (mg/dl) 36.64 ± 2.52a 35.56 ± 2.45a 63.41 ± 5.33b 57.72 ± 4.76c 51.21 ± 4.89d 43.54 ± 3.96e
Creatinine in serum (mg/dl) 0.46 ± 0.05a 0.45 ± 0.05a 0.92 ± 0.09b 0.84 ± 0.06c 0.76 ± 0.04d 0.55 ± 0.05e
Creatinine clearance (ml/min) 0.29 ± 0.05a 0.29 ± 0.05a 0.10 ± 0.03b 0.14 ± 0.03c 0.20 ± 0.04d 0.23 ± 0.04e
a a 0 ± 0.63b c d e
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3.6. Effect of hesperidin on enzymatic antioxidants
Table 5 illustrates the activities of enzymatic antioxi-
dants namely superoxide dismutase, catalase, glutathioneHemoglobin (g/dl blood) 10.90 ± 0.71 11.18 ± 0.93 6.6
alues are mean ± SD for 6 rats in each group. Values are not sharing a c
DN—hesperidin; Fe—ferrous sulfate.
.2. Effect of hesperidin on renal functional markers
Table 2 presents the levels of renal functional mark-
rs in control and experimental rats. In Fe treated rats,
he activities of renal functional markers such as urea,
reatinine, creatinine clearance and hemoglobin were sig-
iﬁcantly increased (p < 0.05). Administration of hesperidin
igniﬁcantly (p < 0.05) reversed these changes in a dose
ependent manner. Our results indicate that hesperidin
t a dose of 80 mg/kg body weight was more effective
han other doses (20 and 40 mg/kg body weight). Hence,
esperidin 80 mg/kg body weight was used for further bio-
hemical studies.
.3. Iron concentration in blood
The concentration of iron has been depicted in Fig. 2.
e administration to normal rats resulted in a signiﬁ-
ant (p < 0.05) increase in concentrations of Fe in blood.
owever, HDN restored the elevated levels signiﬁcantly
p < 0.05) to within normal range in these animals when
ompared to their respective control groups.
.4. Effect of hesperidin on lipid proﬁle
The changes in the levels of serum and tissue lipids in
ormal and experimental rats are illustrated in Table 3. The
evels of serum and tissue (liver & kidney) total cholesterol,
riglycerides (TGs), free fatty acids (FFAs) and phospho-
ipids (PLs) were highly altered in Fe treated rats when
ompared with control group. Oral administration of HDN
o Fe intoxicated rat changes in the levels of serum and
issue total cholesterol, TGs, FFAs and PLs were near to
ormal.7.70 ± 0.50 8.61 ± 0.58 10.74 ± 0.65
 superscript letter (a, b, c, d and e) differ signiﬁcantly at p < 0.05 (DMRT).
3.5. Effect of hesperidin on lipid peroxidation
Table 4 shows the levels of lipid peroxidative mark-
ers (measured by the levels of thiobarbituric acid reactive
substances and lipid hydroperoxides) were signiﬁcantly
increased in the plasma and tissue (liver & kidney) of Fe
treated rats. Administration of HDN signiﬁcantly (p < 0.05)
decreased the levels of thiobarbituric acid reactive sub-
stances and lipid hydroperoxides on iron intoxicated rats.Fig. 2. Effect of hesperidin (HDN) on the accumulation of Fe in blood of
control and. experimental rats. Values are mean ± SD for 6 rats in each
group; values are not sharing a common superscript letter (a, b and c)
differ signiﬁcantly at p < 0.05 (DMRT).
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Table 3
Changes in the levels of Cholesterol, TGs, and PLs in serum and tissues of control and experimental rats.
Groups Control Normal + HDN (80 mg/kg) Normal + Fe (30 mg/kg) Fe (30 mg/kg) + HDN (80 mg/kg)
Cholesterol
Serum 83.45 ± 8.27a 82.14 ± 7.81a 115.97 ± 10.96b 94.57 ± 8.40c
Liver 281.71 ± 20.16a 277.77 ± 20.15a 386.22 ± 30.21b 312.11 ± 25.78c
Kidney 350.71 ± 27.57a 347.190 ± 27.06a 477.91 ± 34.72b 394.30 ± 32.14c
Triglycerides
Serum 73.96 ± 6.59a 71.17 ± 6.57a 120.80 ± 10.16b 85.44 ± 8.13bc
Liver 283.66 ± 16.75a 280.21 ± 16.10a 379.78 ± 3.05b 315.51 ± 22.5c
Kidney 325.11 ± 25.93a 319.56 ± 25.38a 466.38 ± 37.85b 365.83 ± 30.78c
Free fatty acids
Serum 77.64 ± 6.43a 75.74 ± 6.24a 132.90 ± 13.16b 89.58 ± 7.47c
Liver 708.42 ± 52.01a 706.31 ± 51.67a 871.61 ± 72.67b 788.37 ± 59.67c
Kidney 325.11 ± 25.93a 319.56 ± 25.38a 466.38 ± 37.85b 365.83 ± 30.78c
Phospholipids
Serum 13.92 ± 0.83a 14.01 ± 0.96a 7.80 ± 0.94b 12.57 ± 0.72c
Liver 8.87 ± 1.02a 9.05 ± 0.92a 3.87 ± 0.37b 7.49 ± 0.74c
Kidney 5.29 ± 0.25a 5.90 ± 0.54a 1.88 ± 0.65b 4.49 ± 0.71c
Values are mean ± SD for 6 rats in each group. Values are not sharing a common superscript letter (a, b and c) differ signiﬁcantly at p < 0.05 (DMRT).
Cholesterol—mg/dl serum and mg/g tissue; triglycerides—mg/dl serum and mg/g tissue; free fatty acids—mg/dl serum and mg/g tissue; phospholipid–mg/dl
serum and mg/g tissue. HDN—hesperidin, Fe—ferrous sulfate.
Table 4
Changes in the levels of TBARS, lipid hydroperoxides in plasma and tissues of control and experimental rats.
Groups Control Normal + HDN (80 mg/kg) Normal + Fe (30 mg/kg) Fe (30 mg/kg) + HDN (80 mg/kg)
TBARS
Plasma 0.35 ± 0.01a 0.33 ± 0.01a 0.46 ± 0.04b 0.40 ± 0.03c
Liver 8.09 ± 0.64a 7.56 ± 0.56a 15.42 ± 1.42b 9.46 ± 0.78c
Kidney 16.76 ± 1.12a 16.01 ± 0.90a 28.41 ± 2.41b 19.85 ± 1.31c
Lipid hydroperoxides
Plasma 13.02 ± 1.38a 12.85 ± 1.29a 19.77 ± 2.13b 15.91 ± 1.68c
Liver 0.83 ± 0.06a 0.81 ± 0.05a 1.32 ± 0.08b 0.96 ± 0.06c
Kidney 0.66 ± 0.05a 0.64 ± 0.05a 0.97 ± 0.07b 0.76 ± 0.06c
Values are mean ± SD for 6 rats in each group. Values are not sharing a common superscript letter (a, b and c) differ signiﬁcantly at p < 0.05 (DMRT). The levels
of  TBARS were expressed as mM/dl plasma and mM/g  tissue; Lipid hydroperoxides—×10−5 mM/dl plasma and mM/g tissue. HDN—hesperidin, Fe—ferrous
sulfate.
Table 5
Changes in the activities of enzymatic antioxidants in control and experimental rats.
Groups Control Normal + HDN (80 mg/kg) Normal + Fe (30 mg/kg) Fe (30 mg/kg) + HDN (80 mg/kg)
SOD
Liver 7.74 ± 0.56a 8.30 ± 0.81a 5.45 ± 0.32b 6.75 ± 0.45c
Kidney 12.07 ± 0.92a 12.51 ± 1.06a 8.09 ± 0.56b 10.41 ± 0.73c
CAT
Liver 90.51 ± 6.67a 94.42 ± 5.92a 55.04 ± 4.13b 75.21 ± 5.00c
Kidney 48.25 ± 4.06a 51.07 ± 4.28a 32.11 ± 1.91b 40.34 ± 3.19c
GPx
Liver 7.03 ± 0.46a 7.28 ± 0.49a 4.61 ± 0.25b 6.02 ± 0.32c
Kidney 5.46 ± 0.35a 5.52 ± 0.48a 3.22 ± 0.16b 4.76 ± 0.29c
GST
Liver 7.98 ± 0.46a 8.19 ± 0.40a 5.95 ± 0.26b 7.08 ± 0.34c
Kidney 6.09 ± 0.34a 6.15 ± 0.42a 3.97 ± 0.28b 5.54 ± 0.28c
Values are mean ± SD for 6 rats in each group. Values are not sharing a common superscript letter (a, b and c) differ signiﬁcantly at p < 0.05 (DMRT). SOD–one
unit  of enzyme activity was taken as the enzyme reaction, which gave 50% inhibition of NBT reduction in one minute/mg protein; CAT—mol  of H2O2
consumed/min/mg protein; GPx—g of GSH consumed/min/mg protein; GST—moles of CDNB-GSH conjugate formed/min/mg protein. HDN—hesperidin,
Fe—ferrous sulfate.
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Table  6
Changes in the levels of non-enzymatic antioxidants in control and experimental rats.
Groups Control Normal + HDN (80 mg/kg) Normal + Fe (30 mg/kg) Fe (30 mg/kg) + HDN (80 mg/kg)
GSH
Plasma 19.93 ± 1.31a 20.07 ± 1.71a 15.22 ± 1.19b 18.07 ± 1.11c
Liver 4.20 ± 0.21a 4.29 ± 0.30a 2.83 ± 0.16b 3.52 ± 0.23c
Kidney 2.44 ± 0.19a 2.57 ± 0.19a 1.22 ± 0.18b 1.77 ± 0.23c
Vitamin C
Plasma 1.86 ± 0.08a 1.94 ± 0.11a 1.54 ± 0.06b 1.70 ± 0.07c
Liver 1.59 ± 0.05a 1.62 ± 0.05a 1.14 ± 0.04b 1.44 ± 0.06c
Kidney 0.94 ± 0.08a 1.01 ± 0.09a 0.61 ± 0.06b 0.82 ± 0.07c
Vitamin E
Plasma 1.34 ± 0.07a 1.39 ± 0.12a 0.90 ± 0.07b 1.21 ± 0.09c
Liver 0.78 ± 0.06a 0.83 ± 0.07a 0.49 ± 0.04b 0.62 ± 0.05c
Kidney 0.69 ± 0.05a 0.73 ± 0.05a 0.46 ± 0.01b 0.55 ± 0.03c
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evel  of GSH was  expressed as mg/dl plasma and g/mg tissue protein; Th
issue. HDN—hesperidin, Fe—ferrous sulfate.
eroxidase, glutathione-S-transferase in tissue (Liver &
idney) of control and experimental rats. A signiﬁcant
p < 0.05) depletion in the activities of enzymatic antiox-
dants in Fe treated rats was observed. Treatment of HDN
long with Fe increased the levels of enzymatic antioxi-
ants in tissue (liver & kidney).
.7. Effect of hesperidin on non-enzymatic antioxidants
Table 6 shows the changes in the levels of plasma and
issue (liver & kidney) non-enzymatic antioxidants namely
educed glutathione, vitamin C and vitamin E. A signiﬁcant
p < 0.05) decrease in the levels of non-enzymatic antioxi-
ants was noticed in rats treated with Fe when compared to
ontrol rats. Treatment with HDN (80 mg/kg body weight)
long with Fe restored the levels of non-enzymatic antiox-
dants to near normal..8. Histological analysis of liver and kidney
Histological analysis showed that Fe administration
nduces the pathological changes in liver. The liver of
Fig. 3. Histopathology of  superscript letter (a, b and c) differ signiﬁcantly at p < 0.05 (DMRT). The
 of vitamin C and vitamin E were expressed as mg/dl plasma and M/mg
control rats (Fig. 3A) and HDN (Fig. 3B) treated rats showed
a normal architecture. Fe exposure resulted in changes in
liver architecture as indicated by focal necrosis, inﬂam-
matory cell inﬁltration and giant cell formation (Fig. 3C).
Fe along with HDN administration (Fig. 3D) showed near
normal hepatocytes with mild portal inﬂammation.
Histological studies showed that Fe administration
induces the pathological changes in kidney. The focal areas
of hemorrhage and inﬂammation of renal cells (Fig. 3E)
were observed in Fe alone intoxicated rats. Rats admin-
istered with HDN along with Fe showed near normal
appearance of glomerulai and tubules (Fig. 3F). Administra-
tion of HDN to normal rats did not produce any pathological
changes in kidney (Fig. 3G) when compared with normal
control rats (Fig. 3H).
4. DiscussionThe objective of the present work was to investi-
gate the protective effects of hesperidin on iron induced
toxicity in rats. It has been demonstrated for their pro-
tective effect against iron induced toxicity in rats. In the
liver and kidney.
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present study, Liver damage by iron had been assessed
by leakage of enzymes such as aspartate aminotrans-
ferase and alanine aminotransferase, into blood [33,34].
In the present study, higher activities of serum, aspartate
aminotransferase, alanine aminotransferase (an indicator
of hepatocytes mitochondrial damage) have been found in
response to iron overload-induced oxidative stress. Such
increased activities might be attributed to the leakage of
these enzymes from the injured liver cells into the blood
stream because of the altered liver membrane permeabil-
ity [35]. Increase in serum alkaline phosphatase activities
is the indicative of cellular damage due to loss functional
integrity of cell membranes. Lactate dehydrogenase is a
sensitive intracellular enzyme, which increase in serum is
also an indicator of cell damage [36] reported that releasing
of transaminases (aspartate aminotransferase and alanine
aminotransferase) and lactate dehydrogenase from the cell
cytosol can occur secondary to cellular necrosis. Serum
Gamma  glutamyl transferase has been widely used as an
index of liver dysfunction. Recent studies indicating that
serum gamma  glutamyl transferase might be useful in
studying oxidative stress related issues. The products of
the gamma glutamyl transferase reaction may  themselves
lead to increased free radical production, particularly in
the presence of iron [37–39]. Bilirubin is other well known
indicators of tissue damage by toxic substance and their
levels are also substantially increased in iron intoxicated
rats. Hesperidin (80 mg/kg body weight) may  stabilize the
hepatic cellular membrane damage and protect the hepa-
tocytes against toxic effects of iron, which may  decrease the
leakage of the enzymes into blood stream. In this context,
the membrane protective effect of hesperidin has already
been reported [40].
The accumulation of iron in blood was effectively
reduced by hesperidin, which revealed that hesperidin
chelate the iron. Moreover, the hydroxyl groups of hes-
peridin or its active metabolites might bind with iron and
enhanced the excretion of iron, which in consequence
decrease accumulation of iron and reduce the toxic effects
of iron. It is quite well known that hesperidin, a citrus
ﬂavonoid act as antioxidant molecule [41], which can scav-
enge the excess iron in biological system. High dose of Fe
might lead to alterations in lipid metabolism and changes
in the levels of serum and tissue lipids. It may  be due to
accumulation of Fe in liver, which plays a central role in
lipid homeostasis. In our study, we have observed increased
concentrations of serum and tissue lipids such as choles-
terol, TGs, FFAs and PLs in Fe treatment. The observed
increase in the levels of FFAs could due to Fe induced distur-
bances of mitochondrial function, which in turn may  lead
to the inhibition of -oxidation and increased accumula-
tion of FFA in tissues. The Fe induced rise of cholesterol
in serum and tissues may  be due to changes in the gene
expression of hepatic enzymes mainly HMG-COA reduc-
tase. Heavy metal induced change in the gene expression
of HMG-COA reductase has already been reported [42]. The
increased PLs content in Fe intoxicated rats may  be due to
elevation in the levels of FFAs and cholesterol. The antiox-
idant property could also contribute to the protection of
membrane lipids from free radical thereby HDN attenuated
the abnormal dispersion of membrane lipids in circulationorts 2 (2015) 46–55
as well as reduced the excessive generation of more toxic
peroxides, which cause drastic changes in cells and tissues.
Reduced risk of cardiovascular disease is often attributed to
the intake phytochemicals, which lower excessive choles-
terol and/or TGs concentrations [43].
Lipid peroxidation is the process of oxidative degrada-
tion of poly unsaturated fatty acid and the products of lipid
peroxidation inactivate cell constituents by oxidation or
cause oxidative stress by undergoing radical chain reac-
tion ultimately leading to the cell damage [44,45]. Iron is
the most common cofactor within the oxygen handling
biological machinery and, speciﬁcally, lipid peroxidation
of biological membranes is the main pathogenic mech-
anism of iron overload induced tissue damage [46]. The
mitochondrion is a target for iron toxicity, with oxidative
mitochondrial damage and poisoning of enzymes of the tri
carboxylic acid cycle and energy metabolism recognized
as potential targets [47]. Iron is also an essential element
whose redox properties and coordination chemistry suits
it for a number of catalytic and transport functions in liv-
ing cells [48]. However, these same properties render iron
toxic, to a large extent due to its ability to generate reac-
tive oxygen species [49,50]. Iron is a well known inducer
of reactive oxygen species. Its ability to accelerate lipid
peroxidation is well established [51,52]. Harmful effects
of extreme iron deposition in liver are likely during iron
overload, which has been associated with the initiation
and propagation of ROS induced oxidative damage to all
biomacromolecules (proteins, lipids, sugar and DNA) that
can lead to a critical failure of biological functions and ulti-
mately cell death [53]. Free radicals such as superoxide
anion, hydrogen peroxide, hydroxyl radical, which cause
lipid peroxidation, can lead to cell death [54]. It is well
known that excess free iron induces the expression of nitric
oxide, releases the nitric oxide which combines with super-
oxide anions to form “peroxynitrite”, a very toxic mediator
of lipid peroxidation as well as oxidative damage to cellu-
lar membrane [55,56]. Earlier studies have demonstrated
the critical role of iron in the formation of reactive oxy-
gen species that ultimately cause peroxidative damage to
vital cell structures [57]. An effective therapeutic approach
can play a double role in reducing the rate of oxidation -
one by sequestering and chelating cellular iron stores and
other as radical trap (i.e., antioxidant activity) [58]. Since
HDN has shown antioxidant and free radical scavenging
activity [59], the present study primarily ameliorating the
effect of HDN on iron accumulation and oxidative damage
in the liver of iron overloaded rat is studied. Oral adminis-
tration of hesperidin signiﬁcantly inverse the iron induced
peroxidative damage in liver which is evidenced from the
lowered levels of thiobarbituric acid reactive substances
and lipid hydroperoxides. This may  be due to the antiox-
idative effect of hesperidin [60].
An antioxidant is a molecule capable of slowing or pre-
venting the oxidation of other molecules. Oxidation is a
chemical reaction that transfers electrons from a substance
to an oxidizing agent. Oxidation reaction can produce free
radicals, which start chain reactions that damage cells.
Antioxidants terminate these chain reactions by removing
free radical intermediates, and inhibit other oxidation reac-
tions by being oxidized themselves. As a result are often
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educing agents such as thiols, ascorbic acid or polyphenols
61].
The enzymatic antioxidants superoxide dismutase,
atalase and glutathione peroxidase and glutathione-S-
ransferase play a vital role during the process of scaveng-
ng reactive oxygen species or preventing their formation
62]. Superoxide dismutase, catalase and glutathione
eroxidase constitute the major enzymatic antioxidant
efenses which convert active oxygen molecules in to
on-toxic compounds [60]. Superoxide dismutase is a ubiq-
itous enzyme with an essential function in protecting
erobic cells against oxidative stress. It is primarily mito-
hondrial enzyme usually found in the plasma membrane
63]. Catalase is a tetrameric heme protein that undergoes
lternative divalent oxidation and reduction at its active
ite in the presence of hydrogen peroxide [64]. As a sub-
trate for the antioxidant enzyme glutathione peroxidase,
educed glutathione protects cellular constituents from the
amaging effects of peroxides formed in metabolism and
ther reactive oxygen species reaction [65]. Glutathione
eroxidase catalyzes the reaction of hydroperoxides with
educed glutathione to form glutathione disulphide and
he reduction product of the hydroperoxide [66]. The
lutathione-S-transferase is a group of isoenzyme is capa-
le of detoxifying various endogenous and exogenous
ubstances by conjugating reduced glutarhione. In this
ontext, the decreased activities of superoxide dismutase,
atalase and glutathione peroxidase and Glutathione-
-transferase were observed in tissues of Fe-treated
ats. Hesperidin offers protection against oxidative dam-
ge due to the ability of enhanced antioxidant activity
67].
The non-enzymatic antioxidants such as vitamin C, vita-
in  E and reduced glutathione are closely interlinked with
ach other and play an excellent role in protecting the cell
rom lipid peroxidation [68]. Vitamin C is a naturally occur-
ing free radical scavenger which decreases free radical
bility and lipid peroxidation sequence [69]. It regenerates
embrane bound alpha-tocopherol radical and removes
he radical from the lipid to the aqueous phase. It also
rotect tissues from lipid peroxidation both in vivo and
n vitro [70]. Vitamin E is the most important lipo soluble
ntioxidant [71] and has the potential to improve toler-
nce of iron supplementation and prevent further tissue
amage. Excess iron imbalances their levels with excess
OS production thus resulting oxidative stress, followed
y peroxidative decomposition of cellular membrane lipids
hich is a postulated mechanism of hepatocellular injury
n iron overload [72]. Vitamin E scavenges ROS, such as
eroxyl radicals and suppresses lipid peroxidation [73].
he tripeptide GSH is an important endogenous antioxi-
ant which has a major role in restoring other free radical
cavengers and antioxidants such as vitamin C and E to
heir reduced state [71,74]. A number of researchers have
xamined the antioxidant activity and radical scavenging
roperties of hesperidin using a variety of assay systems
75–77]. Treatment with hesperidin in iron-intoxicated
ats protects the depletion of non-enzymatic antioxidants
ia its metal-chelating and antioxidant property [78] and
ay  minimize the usage of these antioxidants, thus restor-
ng their levels.orts 2 (2015) 46–55 53
In the present study, the hepatic histoarchitecture of
the iron treated rats resulted in focal necrosis, inﬂamma-
tory cell inﬁltration and giant cell formation. It might be
due to the formation of highly reactive radicals because
of oxidative threat induced by iron. The accumulated
hydroperoxides can cause cytotoxicity, which is associated
with peroxidation of membrane phospholipids by lipid
hydro peroxides, the basis for cellular damage. The necrotic
conditions coincide with our biochemical studies, which
show increased levels of lipid peroxidation. Administration
of hesperidin reduced the histological alterations induced
by iron. It can be attributed to the antioxidant and chelating
ability of hesperidin, which signiﬁcantly reduced the oxida-
tive threat leading to reduction of pathological changes and
restoration of normal physiological functions.
Histopathological observations in the kidney showed
that Fe induced multiple foci of hemorrhage, necrosis and
cloudy swelling of the tubules. The accumulation of Fe and
its contents in the tissues is the basis for cellular damage.
It is well established that the free radicals and intermedi-
ate products of peroxidation are capable of damaging the
membrane integrity and altering their function, which can
lead to the development of various pathological processes.
Fe preferentially binds to the membrane and disturbs the
redox state of the cells. Hence, the long retention of Fe in
the tissues and increased oxidative state promoted by Fe
might lead to a collapse in membrane integrity and other
pathological changes in liver and kidney.
In conclusion, our results indicates that HDN may  play
a protective role in reducing the toxic effects of Fe-induced
oxidative damage in liver and kidney, which could be due
to its antioxidant potential by scavenging the free radicals.
The present study therefore provides biological evident
supporting the efﬁcacy of HDN against Fe-induced toxicity
in rats.
Transparency document
The Transparency document associated with this article
can be found in the online version.
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